Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines

Journal of Psychiatric Research

Volumn 44, Issue 1, 2010, Pages 32-41

  Sarris, Jerome ^a   Kavanagh, David J ^b   Byrne, Gerard ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Adjunctive; Adjuvant; Antidepressants; Benzodiazepines; Herbal medicine; Kava; Mood stabilizers; St. John's wort

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHINESE DRUG; CITALOPRAM; CLOMIPRAMINE; DOCOSAHEXAENOIC ACID; FLUOXETINE; FOLIC ACID; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; IMIPRAMINE; INOSITOL; JIA WEI XIAO YAO SAN; KAVA EXTRACT; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OMEGA 3 FATTY ACID; PAROXETINE; PLACEBO; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANXIETY DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; DEPRESSION; DIET SUPPLEMENTATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG POTENTIATION; FATIGUE; HERBAL MEDICINE; HUMAN; MAJOR DEPRESSION; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 72149087969     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.06.003     Document Type: Review

References (123)

1. Akhondzadeh B., Moshiri E., Noorbala A., Jamshidi A., Abbasi S., and Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Progress in Neuropsychopharmacology and Biological Psychiatry 30 (2007) 439-442
2. Akhondzadeh S., Fallah-Pour H., Afkham K., Jamshidi A.H., and Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complementary and Alternative Medicine 4 (2004) 12
3. Akhondzadeh S., Kashani L., Fotouhi A., Jarvandi S., Mobaseri M., Moin M., et al. Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. Progress in Neuropsychopharmacology and Biological Psychiatry 27 (2003) 123-127
4. Akhondzadeh S., Tahmacebi-Pour N., Noorbala A.A., Amini H., Fallah-Pour H., Jamshidi A.H., et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy Research 19 (2005) 148-151
5. Alpert J.E., Papakostas G., Mischoulon D., Worthington III J.J., Petersen T., Mahal Y., et al. S-Adenosyl-l-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. Journal of Clinical Psychopharmacology 24 (2004) 661-664
6. Antonijevic I.A. Depressive disorders - is it time to endorse different pathophysiologies?. Psychoneuroendocrinology 31 (2006) 1-15
7. Appleton K.M., Hayward R.C., Gunnell D., Peters T.J., Rogers P.J., Kessler D., et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. American Journal of Clinical Nutrition 84 (2006) 1308-1316
8. Appleton K.M., Peters T.J., Hayward R.C., Heatherley S.V., McNaughton S.A., Rogers P.J., et al. Depressed mood and n-3 polyunsaturated fatty acid intake from fish: non-linear or confounded association?. Social Psychiatry and Psychiatric Epidemiology 42 (2007) 100-104
9. Atmaca M., Tezcan E., Kuloglu M., Ustundag B., and Kirtas O. The effect of extract of Ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry and Clinical Neurosciences 59 (2005) 652-656
10. Ayuso Gutierrez J.L., Lopez-Ibor Alino J.J., and Montejo Iglesias L. Tryptophan and amitriptyline in the treatment of depression (double blind study). Actas Luso Esp Neurol Psiquiatr Cienc Afines 1 (1973) 471-476
11. Beck A.T., Ward C., and Mendelson M. Beck Depression Inventory (BDI). Archives of General Psychiatry 4 (1961) 561-571
12. Belmaker R.H., and Agam G. Major depressive disorder. New England Journal of Medicine 358 (2008) 55-68
13. Berger G.E., Proffitt T.M., McConchie M., Yuen H., Wood S.J., Amminger G.P., et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 68 (2007) 1867-1875
14. Berlanga C., Ortega-Soto H.A., Ontiveros M., and Senties H. Efficacy of S-adenosyl-l-methionine in speeding the onset of action of imipramine. Psychiatry Research 44 (1992) 257-262
15. Berlim M.T., Fleck M.P., and Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Annals of Medicine 40 (2008) 149-159
16. Butterweck V. Mechanism of action of St. John's wort in depression: what is known?. CNS Drugs 17 (2003) 539-562
17. Byerley W.F., Judd L.L., Reimherr F.W., and Grosser B.I. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. Journal of Clinical Psychopharmacology 7 (1987) 127-137
18. Bystritsky A., Kerwin L., and Feusner J.D. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). Journal of Alternative and Complementary Medicine 14 (2008) 175-180
19. Chengappa K., Levine J., Gershon S., Mallinger A., Hardan A., Vagnucci A., et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disorder 2 (2000) 47-55
20. Chiu C.C., Huang S.Y., Chen C.C., and Su K.P. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. Journal of Clinical Psychiatry 66 (2005) 1613-1614
21. CIPS. Internationale skalen fur die psychiatrie (1996), Beltz, Gottingen
22. Coppen A., and Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. Journal of Affective Disorders 60 (2000) 121-130
23. Coppen A., Chaudhry S., and Swade C. Folic acid enhances lithium prophylaxis. Journal of Affective Disorders 10 (1986) 9-13
24. Coppen A., Shaw D.M., and Farrell J.P. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1 (1963) 79-81
25. Darbinyan V., Aslanyan G., Amroyan E., Gabrielyan E., Malmstrom C., and Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nordic Journal of Psychiatry 61 (2007) 343-348
26. Davids E., Bunk C., Specka M., and Gastpar M. Psychotropic drug prescription in a psychiatric university hospital in Germany. Progress in Neuropsychopharmacology and Biological Psychiatry 30 (2006) 1109-1116
27. de la Gandara J., Aguera L., Rojo J.E., Ros S., and de Pedro J.M. Use of antidepressant combinations: which, when and why? Results of a Spanish survey. Acta Psychiatrica Scandinavica Supplemental (2005) 32-36
28. Dorfman-Etrog P., Hermesh H., Prilipko L., Weizman A., and Munitz H. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study. European Neuropsychopharmacology 9 (1999) 475-477
29. Dunlop B.W., and Davis P.G. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Primary Care Companion to the Journal of Clinical Psychiatry 10 (2008) 222-228
30. Eden Evins A., Demopulos C., Yovel I., Culhane M., Ogutha J., Grandin L.D., et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disorder 8 (2006) 168-174
31. Ellen S., Selzer R., Norman T., and Blashki G. Depression and anxiety: pharmacological treatment in general practice. Australian Family Physician 36 (2007) 222-228
32. Emsley R., Niehaus D.J., Koen L., Oosthuizen P.P., Turner H.J., Carey P., et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophrenia Research 84 (2006) 112-120
33. Fava M., and Rush A.J. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychotherapy and Psychosomatics 75 (2006) 139-153
34. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., and Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry 158 (2001) 2071-2074
35. Finfgeld D.L. Serotonin syndrome and the use of SSRIs. Journal of Psychosocial Nursing and Mental Health Services 42 (2004) 16-20
36. Fountoulakis K.N., Vieta E., Sanchez-Moreno J., Kaprinis S.G., Goikolea J.M., and Kaprinis G.S. Treatment guidelines for bipolar disorder: a critical review. Journal of Affective Disorders 86 (2005) 1-10
37. Frangou S., Lewis M., and McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. British Journal of Psychiatry 188 (2006) 46-50
38. Glassman A.H., and Platman S.R. Potentiation of a monoamine oxidase inhibitor by tryptophan. Journal of Psychiatric Research 7 (1969) 83-88
39. Guy W., and Bonato R.E. CGI: Clinical Global Impressions. Manual for the ECDEU assessment battery, 2nd revised ed. (1970), National Institute of Mental Health, Chevy Chase, MD
40. Haddad P.M., and Sharma S.G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21 (2007) 911-936
41. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 32 (1959) 50-55
42. Hamilton M. A rating scale for depression. Journal of Neurology and Neurosurgery in Psychiatry 23 (1960) 56-62
43. Henderson D.C. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. Journal of Clinical Psychiatry 69 (2008) e04
44. Hood S.D., Bell C.J., and Nutt D.J. Acute tryptophan depletion. Part I: Rationale and methodology. Australian and New Zealand Journal of Psychiatry 39 (2005) 558-564
45. Izzo A.A. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. International Journal of Clinical Pharmacology and Therapeutics 42 (2004) 139-148
46. Jazayeri S., Tehrani-Doost T., Keshavarz A., Hosseini M., Djazayery A., and Amini H. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Australian and New Zealand Journal of Psychiatry 42 (2008) 192-198
47. Keck Jr. P.E., Mintz J., McElroy S.L., Freeman M.P., Suppes T., Frye M.A., et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentaenoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biological Psychiatry 60 (2006) 1020-1022
48. Kelly G.S. Rhodiola rosea: a possible plant adaptogen. Alternative Medicine Review 6 (2001) 293-302
49. Knuppel L., and Linde K. Adverse effects of St. John's wort: a systematic review. Journal of Clinical Psychiatry 65 (2004) 1470-1479
50. Lerner V., Bergman J., Statsenko N., and Miodownik C. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 65 (2004) 1550-1554
51. Lerner V., Miodownik C., Kaptsan A., Bersudsky Y., Libov I., Sela B.A., et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. Journal of Clinical Psychiatry 68 (2007) 1648-1654
52. Lerner V., Miodownik C., Kaptsan A., Cohen H., Loewenthal U., and Kotler M. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 63 (2002) 54-58
53. Levine J., Barak Y., Gonzalves M., Szor H., Elizur A., Kofman O., et al. Double-blind, controlled trial of inositol treatment of depression. American Journal of Psychiatry 152 (1995) 792-794
54. Levine J., Mishori A., Susnosky M., Martin M., and Belmaker R.H. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biological Psychiatry 45 (1999) 270-273
55. Levitan R.D., Shen J.H., Jindal R., Driver H.S., Kennedy S.H., and Shapiro C.M. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. Journal of Psychiatry and Neuroscience 25 (2000) 337-346
56. Lin P.Y., and Su K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. Journal of Clinical Psychiatry 68 (2007) 1056-1061
57. Madabushi R., Frank B., Drewelow B., Derendorf H., and Butterweck V. Hyperforin in St. John's wort drug interactions. European Journal of Clinical Pharmacology 62 (2006) 225-233
58. Malsch U., and Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berlin) 157 (2001) 277-283
59. Marangell L.B., Martinez J.M., Zboyan H.A., Kertz B., Kim H.F., and Puryear L.J. A double- blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. American Journal of Psychiatry 160 (2003) 996-998
60. Miklowitz D.J., and Johnson S.L. The psychopathology and treatment of bipolar disorder. Annual Reviews in Clinical Psychology 2 (2006) 199-235
61. Miodownik C., Cohen H., Kotler M., and Lerner V. Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah 142 (2003) 592-596 647
62. Montgomery P., and Richardson A.J. Omega-3 fatty acids for bipolar disorder. Cochrane Database Systematic Reviews (2008) [CD005169]
63. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134 (1979) 382-389
64. Morris D.W., Trivedi M.H., and Rush A.J. Folate and unipolar depression. Journal of Alternative Complementary Medicine 14 (2008) 277-285
65. Morris S. Estimating effect sizes from pretest-posttest-control group designs. Organizational Research Methods 11 (2008) 364-386
66. Moshiri E., Basti A.A., Noorbala A.A., Jamshidi A.H., Hesameddin Abbasi S., and Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine (2006)
67. Nardini M., De Stefano R., Iannuccelli M., Borghesi R., and Battistini N. Treatment of depression with l-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. International Journal Clinical Pharmacology Research 3 (1983) 239-250
68. Nelson J.C. Augmentation strategies in depression 2000. Journal of Clinical Psychiatry 61 Suppl. 2 (2000) 13-19
69. Nemets B., Mishory A., Levine J., and Belmaker R.H. Inositol addition does not improve depression in SSRI treatment failures. Journal of Neural Transmission 106 (1999) 795-798
70. Nemets B., Stahl Z., and Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry 159 (2002) 477-479
71. Nestler E.J., and Carlezon Jr. W.A. The mesolimbic dopamine reward circuit in depression. Biological Psychiatry 59 (2006) 1151-1159
72. Nierenberg A.A., Burt T., Matthews J., and Weiss A.P. Mania associated with St. John's wort. Biological Psychiatry 46 (1999) 1707-1708
73. Noorbala A.A., Akhondzadeh S., Tahmacebi-Pour N., and Jamshidi A.H. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. Journal of Ethnopharmacology 97 (2005) 281-284
74. Oswald P., Souery D., Kasper S., Lecrubier Y., Montgomery S., Wyckaert S., et al. Current issues in bipolar disorder: a critical review. European Neuropsychopharmacology 17 (2007) 687-695
75. Papakostas G.I., Petersen T., Lebowitz B.D., Mischoulon D., Ryan J.L., Nierenberg A.A., et al. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. International Journal of Neuropsychopharmacology 8 (2005) 523-528
76. Parker G., Gibson N., Heruc G., Rees A., and Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. American Journal of Psychiatry 163 (2006) 969-978
77. Patten S.B., and Beck C. Major depression and mental health care utilization in Canada: 1994 to 2000. Canadian Journal of Psychiatry 49 (2004) 303-309
78. Peet M., Brind J., Ramchand C.N., Shah S., and Vankar G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research 49 (2001) 243-251
79. Peet M., and Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives of General Psychiatry 59 (2002) 913-919
80. Preskorn S.H. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. Journal Psychopharmacology 20 (2006) 85-94
81. Raja M., and Azzoni A. Hypericum-induced mood disorders: switch from depression to mixed episodes in two patients. International Journal of Psychiatry in Clinical Practice 10 (2006) 146-148
82. Rathbone J., Zhang L., Zhang M., Xia J., Liu X., and Yang Y. Chinese herbal medicine for schizophrenia. Cochrane Database Systematic Reviews (2005) [CD003444]
83. Resler G., Lavie R., Campos J., Mata S., Urbina M., García A., et al. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes. Neuroimmunomodulation 15 (2008) 145-152
84. Ressler K.J., and Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety 12 Suppl. 1 (2000) 2-19
85. Rickels K., and Rynn M. Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry 63 Suppl. 14 (2002) 9-16
86. Roberts S.H., Bedson E., Hughes D., Lloyd K., Moat S., Pirmohamed M., et al. Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial. BMC Psychiatry 7 (2007) 65
87. Rodriguez-Landa J.F., and Contreras C.M. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine 10 (2003) 688-699
88. Roiser J., McLean A., Ogilvie A., Blackwell A., Bamber D., Goodyer I., et al. The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression. Neuropsychopharmacology 30 (2005) 775-785
89. Rush A.J. STAR*D: what have we learned?. American Journal of Psychiatry 164 (2007) 201-204
90. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163 (2006) 1905-1917
91. Sachs G.S., Thase M.E., Otto M.W., Bauer M., Miklowitz D., Wisniewski S.R., et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry 53 (2003) 1028-1042
92. Schneck C. St. John's wort and hypomania. Journal of Clinical Psychiatry 59 (1998) 689
93. Schulz V. Safety of St. John's wort extract compared to synthetic antidepressants. Phytomedicine 13 (2006) 199-204
94. Shaw D.M., Macsweeney D.A., Hewland R., and Johnson A.L. Tricyclic antidepressants and tryptophan in unipolar depression. Psychological Medicine 5 (1975) 276-278
95. Shaw K., Turner J., and Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Systematic Reviews (2002) [CD003198]
96. Shevtsov V.A., Zholus B.I., Shervarly V.I., Vol'skij V.B., Korovin Y.P., Khristich M.P., et al. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine 10 (2003) 95-105
97. Shriqui C., Bradwejn J., Annable L., and Jones B. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. American Journal of Psychiatry 149 (1992) 391-393
98. Soares-Weiser K., and Fernandez H.H. Tardive dyskinesia. Seminars in Neurology 27 (2007) 159-169
99. Soares K., and McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Systematic Reviews 4 (2001) [CD000209]
100. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Archives of General Psychiatry 56 (1999) 407-412
101. Su K.P., Huang S.Y., Chiu C.C., and Shen W.W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. European Neuropsychopharmacology 13 (2003) 267-271
102. Tapp A., Wood A.E., Secrest L., Erdmann J., Cubberley L., and Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatric Services 54 (2003) 55-59
103. Taylor M.J., Wilder H., Bhagwagar Z., and Geddes J. Inositol for depressive disorders. Cochrane Database Systematic Reviews (2004) [CD004049]
104. Thase M.E. STEP-BD and bipolar depression: what have we learned?. Current Psychiatry Reports 9 (2007) 497-503
105. Thomson J., Rankin H., Ashcroft G.W., Yates C.M., McQueen J.K., and Cummings S.W. The treatment of depression in general practice: a comparison of l-tryptophan, amitriptyline, and a combination of l-tryptophan and amitriptyline with placebo. Psychological Medicine 12 (1982) 741-751
106. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin F., Warden D., et al. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 354 (2006) 1243-1252
107. Tyrer P., and Baldwin D. Generalised anxiety disorder. Lancet 368 (2006) 2156-2166
108. Vaddadi K.S., Courtney P., Gilleard C.J., Manku M.S., and Horrobin D.F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatric Research 27 (1989) 313-323
109. Walinder J., Skott A., Carlsson A., Nagy A., and Bjorn-Erik R. Potentiation of the antidepressant action of clomipramine by tryptophan. Archives in General Psychiatry 33 (1976) 1384-1389
110. Warden D., Rush A.J., Trivedi M.H., Fava M., and Wisniewski S.R. The STAR*D Project results: a comprehensive review of findings. Current Psychiatry Reports 9 (2007) 449-459
111. Werneke U., Taylor T., and Priebe S. Complementary medicines in psychiatry: review of effectiveness and safety. British Journal of Psychiatry 188 (2006) 109-121
112. Williams A.L., Girard C., Jui D., Sabina A., and Katz D.L. S-Adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clinical and Investigative Medicine 28 (2005) 132-139
113. Williamson E.M. Synergy and other interactions in phytomedicines. Phytomedicine 8 (2001) 401-409
114. Yang Z.Y., Zhang W.B., and Liu J.L. Comparative study of modified xiaoyao pill combining amitriptyline on therapeutic effect and compliance in treating patients with depression. Zhongguo Zhong Xi Yi Jie He Za Zhi 27 (2007) 642-644
115. Young R., Biggs J., Ziegler V., and Meyer D. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry (1978) 429-435
116. Zanoli P. Role of hyperforin in the pharmacological activities of St. John's wort. CNS Drug Reviews 10 (2004) 203-218
117. Zarate Jr. C.A., and Quiroz J.A. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disorder 5 (2003) 217-225
118. Zhang H.W., Wang C.Y., Xu H.N., Zhao X., Dai Q., Li J., et al. Clinical study on effect of fluoxetine combined with Chinese medicine or tibetan drugs in treating senile depression in plateau district. Zhongguo Zhong Xi Yi Jie He Za Zhi 26 (2006) 202-204
119. Zhang X.Y., Zhou D.F., Cao L.Y., Xu C.Q., Chen D.C., and Wu G.Y. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. Journal of Clinical Psychopharmacology 24 (2004) 83-86
120. Zhang X.Y., Zhou D.F., Su J.M., and Zhang P.Y. The effect of extract of Ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology 21 (2001) 85-88
121. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Su J.M., and Cao L.Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry 62 (2001) 878-883
122. Zhang Z.J., Kang W.H., Tan Q.R., Li Q., Gao C.G., Zhang F.G., et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. Journal of Psychiatric Research (2005)
123. Zhou S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism 9 (2008) 310-322